Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients
NCT00243529
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
64
Enrollment
OTHER
Sponsor class
Conditions
Melanoma Stage III or IV
Interventions
BIOLOGICAL:
autologous dendritic cell vaccine
Sponsor
Radboud University Medical Center
Collaborators
[object Object]